title: Emerging drugs for migraine treatment.
abstract: BACKGROUND
  Migraine is a highly prevalent and disabling neurological condition whose personal, social and economic impact is substantial. Abortive and preventative treatments of this condition are still unsatisfactory, with poor control of the acute symptoms of the single attacks in many cases and a frequent progression towards chronicity.
  
  
  METHODS
  The major drug classes recently developed and/or in current development for migraine treatment are discussed. These include: Calcitonin-Gene-Related Peptide (CGRP) receptor antagonists, mAbs against CGRP or its receptor, selective 5 hydroxytryptamine (5-HT)1F receptor agonists, drugs targeting Acid-Sensing Ion Channels, Transient Receptor Potential channels and Nitric Oxide.
  
  
  CONCLUSIONS
  The most convincing results appear those obtained with mAbs against CGRP, particularly in migraine preventative treatment, given the absence of serious adverse events, and the good response in terms of pain relief. If these results are confirmed in larger studies, these compounds have the potential to significantly improve the pharmacological control of migraine and also its evolution towards chronicity.
authors.affiliation: "G. D'Annunzio" University, Headache Center, Department of Medicine and Science of Aging , Chieti , Italy.
authors.forename: Maria Adele
authors.initials: MA
authors.lastname: Giamberardino
authors.forename: Paolo
authors.initials: P
authors.lastname: Martelletti
mesh_terms: D000818:Animals; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D002908:Chronic Disease; D018450:Disease Progression; D015195:Drug Design; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D058990:Molecular Targeted Therapy; D016896:Treatment Outcome
chemical_list: D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists
keywords: acid-sensing ion channels; acute and preventative treatment; antibodies against calcitonin gene-related peptide; calcitonin gene-related peptide receptor antagonists; migraine; nitric oxide; selective 5 hydroxytryptamine1F receptor agonists; transient receptor potential channels